Business

Grant of Options, PDMR Dealing

Grant of Options, PDMR Dealing.

articleArecor Therapeutics PlcNovember 25, 20215/company/arecor-therapeutics-plc/news/grant-of-options-pdmr-dealing
Grant of Options, PDMR Dealing

About this update from Arecor Therapeutics Plc

[{"type":"text","content":"\n \n \n \n RNS Number : 5231T\n Arecor Therapeutics PLC\n 25 November 2021\n  \n \n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n  \n \n \n Grant of Options, PDMR Dealing\n \n \n  \n \n \n Cambridge, UK, \n 25 \n November 2021:\n  \n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives\n ,\n  \n announces that \n on 24 November 2021, it granted a total of 87,500 options under the Company's All Employee Share Ownership Plan (\"AESOP Options\") and 75,000 options under the Company's Long Term Incentive Plan (\"LTIP Options\") over new ordinary shares of 0.1 pence each in the Company (\"Ordinary Shares\").\n \n \n The AESOP Options, which vest after 12 months, are exercisable at £4.15, subject to continuous employment, and are exercisable up to ten years from the date of grant. The LTIP Options are exercisable at £0.01, subject to continued employment and the meeting of certain performance conditions, and are exercisable up to ten years from the date of grant. 40,000 of the AESOP Options and 75,000 of the LTIP Options were granted to Lindsey Foulkes, Chief Operating Officer and a PDMR of the Company. Following this grant of options, Lindsey Foulkes holds 115,000 options over Ordinary Shares of the Company.\n \n \n The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.\n \n \n  \n \n \n For further information, please contact:\n \n \n  \n \n \n \n \n \n Arecor Therapeutics plc\n \n \n  \n \n \n \n \n \n www.arecor.com\n \n \n \n \n \n \n \n Dr Sarah Howell, Chief Executive Officer\n \n \n \n \n Tel: +44 (0) 1223 426060\n \n \n Email: \n \n [email protected]\n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Susan Lowther, Chief Financial Officer\n \n \n \n \n Tel: +44 (0) 1223 426060\n \n \n Email: \n \n [email protected]\n \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Mo Noonan, Communications\n \n \n \n \n Tel: +44 (0) 7876 444977\n \n \n Email: \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n \n \n Panmure Gordon (UK) Limited\n \n \n (NOMAD and Broker)\n \n \n Freddy C...

More updates from Arecor Therapeutics Plc